RANKL Inhibition: From Mice to Men (and Women)

  • Marina Stolina
  • Paul J. Kostenuik
  • William C. Dougall
  • Lorraine A. Fitzpatrick
  • Debra J. Zack
Part of the Advances in Experimental Medicine and Biology book series (volume 602)

RANKL, the primary mediator of osteoclast formation, function and survival, is implicated in bone loss across a broad range of conditions. RANK and RANKL are expressed by cells involved in bone remodeling, by cells of the immune system, and by cells in other tissues. Preclinical and clinical data support the following conclusions: 1) The immune and skeletal phenotypes associated with RANKL inhibition differ in important ways from those associated with the complete absence or ablation of RANK or RANKL. 2) Immune challenge performed in animals in the presence of RANKL inhibition demonstrates normal immune function, consistent with the interpretation that RANKL inhibition does not impair the ability of animals to mount an effective immune response. 3) In animal models of inflammatory disease, inhibition of RANKL prevents bone loss but does not show a detectable effect on immune mediators or inflammation. 4) A phase 2 study in postmenopausal women with low BMD using the RANKL inhibitor denosumab showed an increase in BMD with an incidence of adverse events that was similar to placebo and to open-label alendronate. In addition, in a subset of patients tested for immunological markers, there were no clinically meaningful differences in T, B, or NK cell numbers or in immunoglobulin levels across dose or treatment groups.


Bone Loss Immune Challenge Contact Hypersensitivity Denosumab Treatment CD40 Deficiency 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Anderson, D.M., E. Maraskovsky, W.L. Billingsley, W.C. Dougall, M.E. Tometsko, E.R. Roux, M.C. Teepe, R.F. DuBose, D. Cosman, and L. Galibert. 1997. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390: 175–179.CrossRefPubMedGoogle Scholar
  2. Bachmann, M.F., B.R. Wong, R. Josien, R.M. Steinman, A. Oxenius, and Y. Choi. 1999. TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation. J Exp Med 189: 1025–1031.CrossRefPubMedGoogle Scholar
  3. Bekker, P.J., D.L. Holloway, A.S. Rasmussen, R. Murphy, S.W. Martin, P.T. Leese, G.B. Holmes, C.R. Dunstan, and A.M. DePaoli. 2004. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 19: 1059–1066.CrossRefPubMedGoogle Scholar
  4. Boyle, W.J., W.S. Simonet, and D.L. Lacey. 2003. Osteoclast differentiation and activation. Nature 423: 337–342.CrossRefPubMedGoogle Scholar
  5. Bucay, N., I. Sarosi, C.R. Dunstan, S. Morony, J. Tarpley, C. Capparelli, S. Scully, H.L. Tan, W. Xu, D.L. Lacey, W.J. Boyle, and W.S. Simonet. 1998. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12: 1260–1268.CrossRefPubMedGoogle Scholar
  6. Byrne, F.R., S. Morony, K. Warmington, Z. Geng, H.L. Brown, S.A. Flores, M. Fiorino, S.L. Yin, D. Hill, V. Porkess, D. Duryea, J.K. Pretorius, S. Adamu, R. Manoukian, D.M. Danilenko, I. Sarosi, D.L. Lacey, P.J. Kostenuik, and G. Senaldi. 2005. CD4+CD45RBHi T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerin. Gut 54: 78–86.CrossRefPubMedGoogle Scholar
  7. Choi, Y., K.M. Woo, S.H. Ko, Y.J. Lee, S.J. Park, H.M. Kim, and B.S. Kwon. 2001. Osteoclastogenesis is enhanced by activated B cells but suppressed by activated CD8(+) T cells. Eur J Immunol 31: 2179–2188.CrossRefPubMedGoogle Scholar
  8. Dougall, W.C., M. Glaccum, K. Charrier, K. Rohrbach, K. Brasel, T. De Smedt, E. Daro, J. Smith, M.E. Tometsko, C.R. Maliszewski, A. Armstrong, V. Shen, S. Bain, D. Cosman, D. Anderson, P.J. Morrissey, J.J. Peschon, and J. Schuh. 1999. RANK is essential for osteoclast and lymph node development. Genes Dev 13: 2412–2424.CrossRefPubMedGoogle Scholar
  9. Fuller, K., B. Wong, S. Fox, Y. Choi, and T.J. Chambers. 1998. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med 188: 997–1001.CrossRefPubMedGoogle Scholar
  10. Kong, Y.Y., U. Feige, I. Sarosi, B. Bolon, A. Tafuri, S. Morony, C. Capparelli, J. Li, R. Elliott, S. McCabe, T. Wong, G. Campagnuolo, E. Moran, E.R. Bogoch, G. Van, L.T. Nguyen, P.S. Ohashi, D.L. Lacey, E. Fish, W.J. Boyle, and J.M. Penninger. 1999. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402: 304–309.CrossRefPubMedGoogle Scholar
  11. Kong, Y.Y., H. Yoshida, I. Sarosi, H.L. Tan, E. Timms, C. Capparelli, S. Morony, A.J. Oliveira-dos-Santos, G. Van, A. Itie, W. Khoo, A. Wakeham, C.R. Dunstan, D.L. Lacey, T.W. Mak, W.J. Boyle, and J.M. Penninger. 1999. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397: 315–323.CrossRefPubMedGoogle Scholar
  12. Lacey, D.L., H.L. Tan, J. Lu, S. Kaufman, G. Van, W. Qiu, A. Rattan, S. Scully, F. Fletcher, T. Juan, M. Kelley, T.L. Burgess, W.J. Boyle, and A.J. Polverino. 2000. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol 157: 435–448.PubMedGoogle Scholar
  13. Lacey, D.L., E. Timms, H.L. Tan, M.J. Kelley, C.R. Dunstan, T. Burgess, R. Elliott, A. Colombero, G. Elliott, S. Scully, H. Hsu, J. Sullivan, N. Hawkins, E. Davy, C. Capparelli, A. Eli, Y.X. Qian, S. Kaufman, I. Sarosi, V. Shalhoub, G. Senaldi, J. Guo, J. Delaney, and W.J. Boyle. 1998. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165–176.CrossRefPubMedGoogle Scholar
  14. Lougaris, V., R. Badolato, S. Ferrari, and A. Plebani. 2005. Hyper immunoglobulin M syndrome due to CD40 deficiency: clinical, molecular, and immunological features. Immunol Rev 203: 48–66.CrossRefPubMedGoogle Scholar
  15. McClung, M.R., E.M. Lewiecki, S.B. Cohen, M.A. Bolognese, G.C. Woodson, A.H. Moffett, M. Peacock, P.D. Miller, S.N. Lederman, C.H. Chesnut, D. Lain, A.J. Kivitz, D.L. Holloway, C. Zhang, M.C. Peterson, and P.J. Bekker. 2006. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354: 821–831.CrossRefPubMedGoogle Scholar
  16. Mebius, R.E. 2003. Organogenesis of lymphoid tissues. Nat Rev Immunol 3: 292–303.CrossRefPubMedGoogle Scholar
  17. Miller, R.E., D. Branstetter, J. Jones, L. Cowan, and W.C. Dougall. 2005. The RANKL inhibitor RANK-Fc has potent antiresorptive efficacy but does not affect host immune responses to influenza infection. J Bone Miner Res 20(Suppl. 1): S293 [Abstract].CrossRefGoogle Scholar
  18. Mizuno, A., N. Amizuka, K. Irie, A. Murakami, N. Fujise, T. Kanno, Y. Sato, N. Nakagawa, H. Yasuda, S. Mochizuki, T. Gomibuchi, K. Yano, N. Shima, N. Washida, E. Tsuda, T. Morinaga, K. Higashio, and H. Ozawa. 1998. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 247: 610–615.CrossRefPubMedGoogle Scholar
  19. Redlich, K., S. Hayer, A. Maier, C.R. Dunstan, M. Tohidast-Akrad, S. Lang, B. Turk, P. Pietschmann, W. Woloszczuk, S. Haralambous, G. Kollias, G. Steiner, J.S. Smolen, and G. Schett. 2002. Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum 46: 785–792.CrossRefPubMedGoogle Scholar
  20. Romas, E., N.A. Sims, D.K. Hards, M. Lindsay, J.W. Quinn, P.F. Ryan, C.R. Dunstan, T.J. Martin, and M.T. Gillespie. 2002. Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am J Pathol 161: 1419–1427.PubMedGoogle Scholar
  21. Simonet, W.S., D.L. Lacey, C.R. Dunstan, M. Kelley, M.S. Chang, R. Luthy, H.Q. Nguyen, S. Wooden, L. Bennett, T. Boone, G. Shimamoto, M. DeRose, R. Elliott, A. Colombero, H.L. Tan, G. Trail, J. Sullivan, E. Davy, N. Bucay, L. Renshaw-Gegg, T.M. Hughes, D. Hill, W. Pattison, P. Campbell, S. Sander, G. Van, J. Tarpley, P. Derby, R. Lee, and W.J. Boyle. 1997. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89: 309–319.CrossRefPubMedGoogle Scholar
  22. Stolina, M., J. Guo, R. Faggioni, H. Brown, and G. Senaldi. 2003. Regulatory effects of osteoprotegerin on cellular and humoral immune responses. Clin Immunol 109: 347–354.CrossRefPubMedGoogle Scholar
  23. Wong, B.R., R. Josien, S.Y. Lee, B. Sauter, H.L. Li, R.M. Steinman, and Y. Choi. 1997. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med 186: 2075–2080.CrossRefPubMedGoogle Scholar
  24. Yasuda, H., N. Shima, N. Nakagawa, K. Yamaguchi, M. Kinosaki, S. Mochizuki, A. Tomoyasu, K. Yano, M. Goto, A. Murakami, E. Tsuda, T. Morinaga, K. Higashio, N. Udagawa, N. Takahashi, and T. Suda. 1998. Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95: 3597–3602.CrossRefPubMedGoogle Scholar
  25. Yun, T.J., P.M. Chaudhary, G.L. Shu, J.K. Frazer, M.K. Ewings, S.M. Schwartz, V. Pascual, L.E. Hood, and E.A. Clark. 1998. OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. J Immunol 161: 6113–6121.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Marina Stolina
    • 1
  • Paul J. Kostenuik
    • 1
  • William C. Dougall
    • 2
  • Lorraine A. Fitzpatrick
    • 3
  • Debra J. Zack
    • 4
  1. 1.Department of Metabolic DisordersAmgen Inc.Thousand OaksUSA
  2. 2.Department of OncologyAmgen Inc.SeattleUSA
  3. 3.Clinical Development, Bone Therapeutic AreaAmgen Inc.Thousand OaksUSA
  4. 4.Clinical Development, Inflammation Therapeutic AreaAmgen Inc.Thousand OaksUSA

Personalised recommendations